477600-74-1

• 常用中文名：N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺
• 常用英文名：N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• CAS号：477600-74-1
• 分子式：C₁₃H₁₉N₅
• 分子量：245.324
• 发布时间：2018-12-22 12:06:42
• 更新时间：2026-07-04 19:28:07

名称

• 中文名: N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺
• 英文名: N-methyl-N-[(3R,4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
• 中文别名: 托法替布杂质M; 托法替尼中间体32; (3R,4R)-甲基-(4-甲基-哌啶-3-基)-(7H-吡咯并[2,3-D]嘧啶-4-基)胺; 托法替尼杂质41; 托法替尼 N-去氰乙酰杂质; N-甲基-N-((3R,4R)-4-甲基-3-哌啶基)-7H-吡咯并[2,3-D]嘧啶-4-胺; n-甲基-n-[(3r,4r)-4-甲基-3-哌啶基]-7H-吡咯并[2,3-d]嘧啶-4-胺; 托法替尼杂质32; 托伐替尼杂质F; N-甲基-N-((3R,4R)-4-甲基-3-哌啶基)-7H-吡咯并[2,3-D]嘧啶-4-胺N-METHYL-N-[(3R,4R)-4-METHYLPIPERIDIN-3-YL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; 台历托法替尼; 托伐替尼杂质M; 托法替尼杂质; 托法替尼杂质 L; 托法替布杂质18(N-甲基-N-((3R,4R)-4-甲基哌啶-3-基)-7H-吡咯并[2,3-D]嘧啶-4-胺); TRK融合基因蛋白重组兔单抗; 托法替尼杂质(M9-RR); 托法替尼杂质M(3S,4R); 托法替布C006非对应异构体(盐酸盐)
• 英文别名: Tofacitinib Impurity-M(debenzylated); N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 477-1; Tofacitinib-11; (3R,4R)-Methyl{(4-Methylpiperidin-3-yl)(7H-pyrrolo[2,3-d]pyriMidin-4-yl)}aMine; TF-G; 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]; Tofacitinib N-Descyanoacetyl; Azilstan medoxomil impurity343; N-methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-1H-pyrrolo[2,3-d]pyrimidin-4-amine; N-METHYL-N-((3R,4R)-4-METHYLPIPERIDIN-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE (CAS NO.477-1); H-Pyrrolo[2,3-d]pyriMidin-4-aMine; N-Methyl-N-[(3R,4R)-4-Methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]; Tofacitinib N-1; tofacitinib intermediate; N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine bis(2,2,2-trifluoroacetate); Tofatinib Impurity 41; N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amin; Tofatinib Impurity F; (3R,4R)-N,4-diMethyl-N-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}piperidin-3-aMine; Tofacitinib IMpurity M; N-Methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-1H-Pyrrolo[2,3-d]pyrimidin-4-amine; Tofacitinib impurity 7/N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7HMethylpiperidin-3-yl)-7Hpyrrolo[ 2,3-d]pyriMidin-4-aMine; Tofacitinib N-Descyanoacetyl Impurity; TOFACITINIB AMINE IMPURITY; 1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- (9CI); N-Methyl-N-((3R,4R)-4-Methyl-piperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine; N-Methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; Tofacitinib Impurity M; 1H-Pyrrolo[2,3-d]pyrimidin-4-amine,N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]

物化性质

• 密度: 1.2±0.1 g/cm3
• 分子式: C₁₃H₁₉N₅
• 分子量: 245.324
• 精确质量: 245.164047
• PSA: 56.84000
• LogP: 1.54
• 折射率: 1.637
• 储存条件: 2-8°C，避光，干燥，密封

安全

• 危害码 (欧洲): Xi

合成路线

1450663-24-7 ~92% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

24211-54-9 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-76-0 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

1500-85-2 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-77-1 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-78-2 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-79-3 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-86-2 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

176966-87-3 ~% 477600-74-1

文献：Tetrahedron Letters, , vol. 54, # 37 p. 5096 - 5098

上下游产品

上游产品  4
24211-54-9 1500-85-2 176966-77-1 176966-79-3
下游产品  0